Allergy

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.

A recent cohort study of 20 emergency departments assessed allergic contact dermatitis cases.

A discussion on research into allergic contact dermatitis and its connection to allergens in skincare products.

DBV Technologies is expected to provide additional updates after a consultation with the FDA.

French researchers find that targeted allergy assessments may be needed in children with peanut allergies.

There is a high risk for contact dermatitis in retail products for skincare, due to the prevalence of allergens.

A recent study in Finland finds 2 major contributing factors to allergic disease in infants with familial risk.

In particular, airway epithelial cells (AEC) in allergic asthmatic (AA) were shown to upregulate mucus metaplasia, matrix-remodeling, and glycolytic programs while failing to upregulate antioxidant genes.

Children with unconfirmed PALs have prolonged hospital stays, higher rates of adverse events, and more infections due to Clostridium difficile and vancomycin-resistant Enterococcus.

Up to 100 participants who experienced an allergic reaction to the vaccine will be enrolled in the single-site trial, which will be led by Dr. Pamela A. Guerrerio

The novel technology combines daily disposable contact lenses with ketotifen in a first in its new category approval.

The algorithm also resulted in a large reduction in oral food challenges.

Additionally, the association between atopic dermatitis and sensitization to eggs was more common during the pandemic then in years prior.

This decision could further exacerbate health inequities among populations that are socioeconomically disadvantaged.

Patients with allergic asthma could often have no clinical history of atopic dermatitis.

In data presented at AAAAI 2022, investigators examined anaphylaxis rates in Brooklyn between 2016-2019.

Investigators from the Cincinnati Children’s Hospital Medical Center tested a new allergic reaction severity grading system.

Dr. Epstein provides updates on a joint study between members of AAAAI and the American College of Allergy on the relationship between epinephrine and post-immunotherapy injection waiting periods.

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

The American College of Allergy, Asthma, and Immunology identify key practices for addressing allergies during the COVID-19 pandemic.

Data pooled from 5 trials show a consistent and manageable safety profile for continued treatment with PALFORZIA.

Prior studies have predominantly considered the associations of respiratory allergy and skin allergy in patients with ADHD, with inconsistent data on food allergy.

Rebecca Rosenberger discusses allergic and non-allergic triggers, and how patients with food allergies can avoid allergic reactions through the winter season.

Allergists discuss the differing opinions of allergies and optimizing patient care during the COVID-19 pandemic.

Investigators recommended the development and validation of a screening tool for FAA that transcends the current food allergy-specific measures.

Investigators reported that the medication was safe for patients with moderate-to-severe atopic dermatitis regardless of the presence of allergic comorbidities.

Data from the LIBERTY AD ADOL trial showed that adolescent patients with moderate-to-severe atopic dermatitis treated with the biologic reported decreases in total and allergen-specific IgE levels for cat dander, peanuts, and more.